Tirzepatide
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Diabetes Mellitus, Type 2
Conditions
Diabetes Mellitus, Type 2, Overweight, Obesity
Trial Timeline
Jan 14, 2026 → Oct 1, 2026
NCT ID
NCT07299084About Tirzepatide
Tirzepatide is a phase 1 stage product being developed by Eli Lilly for Diabetes Mellitus, Type 2. The current trial status is recruiting. This product is registered under clinical trial identifier NCT07299084. Target conditions include Diabetes Mellitus, Type 2, Overweight, Obesity.
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07438444 | Approved | Recruiting |
| NCT07299084 | Phase 1 | Recruiting |
| NCT07247084 | Approved | Recruiting |
| NCT06857942 | Approved | Recruiting |
| NCT06864026 | Approved | Recruiting |
| NCT06635057 | Approved | Active |
| NCT05912621 | Phase 2 | Recruiting |
| NCT05978713 | Phase 1 | Completed |
| NCT05810597 | Phase 1 | Completed |
| NCT05706506 | Approved | Completed |
| NCT04844918 | Phase 3 | Completed |
| NCT04847557 | Phase 3 | Completed |
| NCT04657003 | Phase 3 | Completed |
| NCT04660643 | Phase 3 | Completed |
| NCT04657016 | Phase 3 | Completed |
| NCT04050670 | Phase 1 | Completed |
| NCT04004988 | Phase 1 | Completed |
| NCT03940742 | Phase 1 | Completed |
| NCT03482024 | Phase 1 | Completed |
Competing Products
20 competing products in Diabetes Mellitus, Type 2